Table 1.

Predictors of outcome in stage III melanoma patients

ComparisonCut-offHR (CI)Log rank P
(A) PD-L1 positive vs. PD-L1 negative>0%0.28 (0.12–0.66)0.002
(B) PD-L1 low vs. PD-L1 negative>0%0.35 (0.14–0.87)0.019
(C) NSM burden high>2030.35 (0.15–0.81)0.010
(D) CD8A high0.20 (0.05–0.87)0.017
  • NOTE: Optimal cutoffs calculated on the basis of ROC curve and Manhattan distance method. HRs and CIs calculated for each variable. A) PD-L1–positive status was a marker of better outcome. B) PD-L1 low patients (<10% PD-L1) had significantly better outcome than PD-L1–negative patients. C) NSM burden high (>203 NSM) was a marker of better outcome. D) High CD8A gene expression was a marker of better outcome.